U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07571200) titled 'A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)' on April 30.
Brief Summary: Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group. The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosi...